Dear Friends and Colleagues,
It is our great pleasure to invite you to the International Symposium on Homologous Recombination and DNA Repair: From Bench to Clinic 2025, taking place on June 26–27, 2025, at the Biomedical Research Foundation of the Academy of Athens.
The meeting will focus on the mechanisms involved in DNA Damage Repair (DDR) and the development of new anticancer therapeutic possibilities. This symposium will bring together academics, molecular and translational biologists as well as clinicians covering a wide range of expertise, including clinical and laboratory medicine, basic science, diagnostics and the private sector. The event will explore fundamental aspects of DNA repair, with a focus on homologous recombination, molecular tools for identifying tumours with DNA repair deficiencies, and the latest clinical advancements in the field. The biology behind DDR and genomic instability constitutes the basis for the effective development of new therapeutic anticancer approaches including immunotherapy and targeted DNA damaging agents.
Key topics include:
- Basic biology of DNA damage response, with an emphasis on homologous recombination
- Development of inhibitors leveraging synthetic lethality
- Current and emerging methodologies for detecting homologous recombination deficiency for patient stratification
- Clinical applications of DNA repair inhibitors, alone or in combination with other therapies, across various tumour types.
There will be short oral presentations of selected posters as well as an open poster session.
The meeting also offers the opportunity to Biotechnology companies to present their latest technological developments and projects in the exhibition space.
We welcome scientists, clinicians, students, and healthcare professionals interested in DNA repair to join us for this exciting event.
Warm regards,
The Organizing Committee
Pr. Α. Klinakis Biochemical Research Foundation Academy of Athens (BRFAA), GR
Dr. P. Constantoulakis PhD GENOTYPOS MSA, Athens, GR
Pr. W. Niedzwiedz PhD The Institute of Cancer Research, London, UK
Dr. J. Loizou PhD The Institute of Cancer Research, London, UK
Dr. S. Linardopoulos PhD Oncology AstraZeneca, Cambridge, UK
* English is the official language of the meeting
- M. Albertella Senior Director, Bioscience, AstraZeneca Oncology R&D, Cambridge, UK
- R. Chapman MRC Weatherall Institute of Molecular Medicine, University of Oxford, UK
- E. Christoforou Senior Scientist, AstraZeneca, Early Oncology R&D, Translational Medicine Epigenomics, UK
- D. Dangaj PhD, Lecturer Ludwig Institute for Cancer Research, Lausanne, CH
- G. Garinis Department of Biology, University of Crete, GR
- I. Gounaris MD, PhD, Vice President P, Merck KGaA, DE
- E. Guerini Rocco MD, Division of Pathology, European Institute of Oncology IRCCS, University of Milan, Milano, IT
- A. Halazonetis Professor, Dept of Molecular and Cellular Biology, University of Geneva, Switzerland
- U. Malapelle Department of Public Health, University Federico II of Naples, Naples, Italy
- W. Niedzwiedz Institute of Cancer Research, London, UK
- Th. Rampias PhD, Biochemical Research Foundation Academy of Athens (BRFAA),GR
- S. J. Sammut MD, PhD, Toby Robins Research Centre, Royal Marsden Hospital, London, UK
The Scientific Committee welcomes the submission of abstracts to the International Symposium on Targeting Homologous Recombination: From Bench to Clinic 2025. Abstracts have to be submitted through the website, using the relevant form. Abstracts will be selected on their scientific merit.
An individual can submit one or more abstracts as presenter or first author. Abstract submission will open from March 17th 2025. Abstracts will not be accepted if sent by fax, e-mail or hard copy (paper copy). Replacing or correcting an abstract submission: Do not resubmit an abstract through the web site. Any corrections should be made by e-mail to the meeting Secretariat (info@scep.gr)
Submission deadline: Abstract submission will close on Friday, June 6th 2025. The Scientific Committee will evaluate all abstracts submitted for presentation. The authors will be notified regarding acceptance of their abstracts by June 16th, 2025.